Journey Medical gains as US FDA approves skin condition drug

Journey Medical

04/11/2024 12:32

** Shares of Journey Medical Corp  DERM.O  rise 13.13% to
$6.98 premarket
    ** U.S. Food and Drug Administration approves co's drug for
treating rosacea, a skin condition that causes long-term redness
on the face and small pus-filled bumps
    ** Drug branded as Emrosi was approved for treating
inflammatory lesions caused by rosacea
     ** DERM anticipates initial supply of the drug will be
available late in Q1 or early Q2 of next year
    ** Up to last close, stock up ~7% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))